Human fetal livers (FL), between 16 and 24 weeks of gestation, were studied for their potential as a source of hematopoietic stem cells for prenatal and postnatal transplantation. In this report we give a quantitative evaluation of human FL as a source of candidate stem cells, and develop a protocol for the isolation of these cells free of microbial contaminants and almost free of mature T cells. Human FLs contained a median 1.9 ؋ 10 9 viable cells and a mean of 1. 2,3 Some promising results were reported with the transplantation of FL cells in humans, either before or after birth.
nant and non-malignant hematological diseases. Shortages in HLA-identical bone marrow (BM), often the best source of HSCs for transplantation, will undoubtedly stimulate a search for alternative sources of HSCs. The observation by Touraine et al 1 that in utero transplantation of fetal liver (FL) HSCs could lead to engraftment in human fetuses prompted several studies of FL to evaluate its potential as a source of reconstituting HSCs. In vitro studies demonstrated the proliferative advantage of fetal tissues over adult BM. 2, 3 Some promising results were reported with the transplantation of FL cells in humans, either before or after birth. 1, [4] [5] [6] [7] [8] However, factors limiting the use of first trimester FL cells became apparent. Among these are the difficulties in harvesting liver at early gestational ages, the relatively low number of cells available from a single first trimester FL and the risk of microbial contamination of the FL tissues. Nonetheless, we have reported recently on a procedure for obtaining first-trimester FL that addresses the ethical concerns regarding such an endeavor and we also demonstrated that after minimal processing these FLs were free of microbial and specific viral contaminants. Thus, a bank of cryopreserved first-trimester FLs was established, but its utility is limited to pre-natal transplantation because of the small size of the samples. 9 We hypothesized that mid-trimester FLs, between the gestational ages of 16 and 24 weeks, represented an abundant source of HSCs that could be made safe for transplantation. It was the goal of this study to determine the potential yield of progenitors and HSCs that could be harvested from mid-trimester FLs and to estimate the risk of graftversus-host disease from mature T and NK cells. In this study we also define a protocol for the processing of human fetal HSC. The aim was to define a method of processing FLs that ensures the highest yield possible of committed progenitors and HSCs without compromising the quality of the grafts. The magnetic cell separation system, Isolex 50, was chosen for this task. The quality of the processed grafts was measured in terms of bacterial and fungal contamination in addition to the enumeration of T cells, progenitors and HSCs.
Materials and methods

Antibodies
The following phycoerythrin (PE)-labeled, or fluorescein isothiocyanate (FITC)-labeled, monoclonal antibodies (MoAb) were purchased from Becton Dickinson (San Jose, CA, USA) or an otherwise stated vendor: mouse IgG1-PE, mouse IgG1-FITC, CD3-PE (SK7), CD3-FITC (SK7), CD4-PE (SK3), CD34-PE (8G12), CD34-FITC (8G12), CD34 (9C5) from Baxter (Irvine, CA, USA), CD34-FITC (581) from Caltag Laboratories (South San Francisco, CA, USA), CD38-PE (HB-7), CD56-PE (MY31), CDw90-PE (5E10) from Pharmingen, San Diego, CA, USA. MoAb 10FM7 against glycophorin A (GPA) was obtained from the American Type Culture Collection and purified ascites was produced in our laboratory.
Human fetal liver procurement
Human FL was obtained from elective abortions by cervical dilatation and instrumental extraction at our institute or from Advanced Bioscience Resources (Alameda, CA, USA) and used under the approval of the Committee of Human Research at our institute. The gestational age of the abortuses ranged from 16 to 24 weeks of amenorrhea and was approximated from the foot length of the fetus. Transportation medium (PBS/BSA) consisted of phosphate-buffered saline (PBS) supplemented with 0.5% bovine serum albumin (BSA; Boehringer Mannheim Biochemicals, Indianapolis, IN, USA), and 50 g/ml gentamicin sulfate (Gibco BRL, Grand Island, NY, USA). More recently, this single antibiotic solution was changed for a combination of erythromycin lactobionate (100 g/ml), gentamicin sulfate (50 g/ml), vancomicin hydrochloride (100 g/ml), and amphotericin B (2.5 g/ml). Livers were transported on ice and usually processed within 2 to 4 h of abortion.
Preparations of fetal liver cells using density gradients, red cell depletion and/or sedimentation techniques
FLs were homogenized through a No. 50 wire mesh (Sigma Chemical, St Louis, MO, USA), washed once by centrifugation and resuspended in 50 ml of PBS/BSA. Aliquots of total fetal liver (TFL) suspension were kept for phenotypic analyses and CFC assays. Cell counts were performed by diluting the cells in trypan blue and all live cells, including mature and immature red cells, counted using a hemocytometer. Alternatively, cell counts were made using a Coulter counter. These suspensions of TFL cells were used to test several techniques for the isolation of hematopoietic progenitors.
Light-density fetal liver (LDFL) cells were isolated using either a 1.077 g/ml solution of Lymphoprep (Nycomed Pharma, Oslo, Norway) or a 1.085 g/ml solution of saline buffered Accudenz (Accurate Chemical and Scientific Corporation, Westbury, NY, USA) as previously described. [9] [10] [11] In some experiments, LDFL cells were further depleted of erythroid cells (GPA Ϫ LDFL) by labeling with a saturating amount of anti-GPA mAb followed by a 15-min magnetic-bead depletion with sheep anti-mouse IgG coated Dynabeads (Dynal, Great Neck, NY, USA).
We also tested the efficiency of 3% gelatin and 5% albumin sedimentation to dispose of clumps of dead liver cells without significant loss of CD34 ϩ/ϩϩ cells. 12 TFL suspensions were divided to test each of these procedures. 3% gelatin was prepared by dissolving 3 g gelatin (JT Baker, Philipsburg, NJ, USA) in 100 ml of 0.9% saline prewarmed in a 30°C water bath. The TFL suspension was mixed with an equal volume of 3% gelatin. The sample was allowed to sediment at 30°C for a maximum of 20 min. The white cell-rich supernatant was collected while the pellet was diluted in 20 ml PBS/BSA and subjected to a second gelatin sedimentation. The two leukocyte-rich supernatants were pooled and washed by centrifugation in PBS/BSA; the remaining pellet was washed as above in PBS/BSA. 5% human serum albumin (HSA) (Baxter Healthcare, Glendale, CA, USA) was also tested as a sedimentation medium; TFL cells were layered on 5% HSA and allowed to sediment vertically at room temperature for a maximum of 20 min or until the sedimentation of clumps was seen. The supernatant was collected and both supernatant and pellet were washed separately before analysis.
In another series of experiments 25% HSA (Baxter Healthcare) was tested as a medium for density-gradient separation of TFL cells. TFL cell suspensions were layered on 25% HSA and centrifuged at 1000 g for 30 min. The interface between the sedimented cells and the supernatant was collected and both supernatant and pellet were washed separately as above. Cell counting and cell surface expression of the CD34 antigen was performed on the initial TFL cells and on the final supernatant and pellet collected after each procedure.
Selection of CD34
ϩ/ϩϩ cells using the Isolex 50 magnetic cell separation system Whole FLs were bathed in two 5-15 min baths at room temperature in a working buffer consisting of PBS with 1% HSA and antibiotics. After washing, the FLs were ground through a No. 50 wire mesh and passed through a second 105 m mesh in a volume of 100 ml. This starting TFL solution was centrifuged for 7 min, 400 g at 4°C and resuspended in 16 ml working buffer.
Further separation used the Isolex 50 magnetic cell separation system (Baxter Healthcare Immunotherapy Division, Irvine, CA, USA) as recommended by the manufacturer with minor modifications as follows. All work was done at room temperature except incubations with the MoAb. Working buffer with antibiotics was used until the final wash of rosetted cells, before the use of the releasing agent, at which time antibiotics were withheld from the working medium. The TFL solution was incubated for 15 min after the addition of 2 ml 5% human immunoglobulin (5% huIgG) (Baxter) to prevent non-specific binding of the CD34 MoAb. Target cells were labeled with 2 ml CD34 MoAb (9C5) in PBS without NaN 3 , incubated for 25 min, washed twice and resuspended in 10 ml working buffer. This solution was gently filtered through a 70 m nylon mesh (Falcon, Becton Dickinson) to remove cell clumps which had formed during the CD34 labelling procedure. An additional 10 ml working buffer was used to wash cells through the sieve, but care was taken not to force the cell clumps through. The labeled cells were then mixed with 3 ml of 5% huIgG and 2.5 ml washed sterile Dynabeads M-450 in an Isolex 50 magnetic cell separator (Fenwal, Deerfield, IL, USA) and incubated for 30 min on a rocking platform at room temperature. The chamber was placed against the magnets and unrosetted, non-target cells drained from the chamber with four washes of 20 ml each. The remaining target cells were released from the beads by 30 min incubation on a rocking platform with 4 ml of PR34 ϩ stem cell releasing agent in a total volume of 20 ml. The releasing agent competes for the binding of the MoAb anti-CD34 with the CD34 expressed on the target cells. Target cells were drained from the chamber with two washes, centrifuged at 400 g for 7 min and resuspended in 2 ml of working buffer. This final solution of selected cells was kept for phenotypic analysis, CFC assays and testing for microbial culture. Purity and yield of CD34 ϩ/ϩϩ cells was calculated based on cell counts and the results of FACS analyses.
Flow cytometric analysis of FL cells
The expression of cell surface antigens was determined by flow cytometry using a FACSCalibur (Becton Dickinson) as previously described. 13 Propidium iodide (PI) (Sigma Chemical) was used to stain dead cells and was added to all samples immediately prior to analysis at a concentration of 1 g/ml. 200 000 to 500 000 events were collected using a live-cell (PI Ϫ ) gate.
CFC assays
Progenitors with myeloid potential were assayed in a similar manner as previously described under serum-deprived culture conditions. 11, 13 A modified formulation of a previously described serum-deprived culture medium was used consisting of Iscove's modified Dulbecco's medium (IMDM) (Sigma Chemical) supplemented with 7.5 ϫ 10 Ϫ5 m ␣-thioglycerol (Sigma Chemical), 50 g/ml gentamicin, 2% fraction-V ethanol-extracted BSA, 200 g/ml human iron-saturated transferrin (Boehringer Mannheim Biochemicals), 10 g/ml recombinant human insulin (Boehringer Mannheim Biochemicals), and 20 g protein/ml human low density lipoprotein (Sigma Chemical).
14 Alternatively, fetal bovine serum (FBS) was used at 20% to supplement cultures grown in IMDM with 50 g/ml gentamycin. FBS was obtained from StemCell Technologies (Vancouver, Canada) and Gemini-BioProducts (Calabasas, CA, USA).
Progenitors were assayed in double-layered clonal cultures as previously described. 11 The cytokine combination of recombinant human c-kit ligand (KL; R&D Systems, Minneapolis, MN, USA) and recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF; Immunex Corporation, Seattle WA, USA), which has been shown to stimulate a high frequency as well as a broad spectrum of fetal hematopoietic progenitors, 13 was added to the bottom layer of the cultures. Both cytokines were used at a final concentration of 20 ng/ml. Primary CFC were determined from triplicate cultures of 1.0 ϫ 10 5 TFL cells and 3.0 ϫ 10 2 to 6.0 ϫ 10 2 CD34 ϩ/ϩϩ selected FL cells/culture. Cultures were scored for the growth of two types of progenitors based on colony size: low proliferative potential colony-forming cells (LPP-CFC) were defined as progenitors giving rise to colonies of у50 cells but smaller than colonies derived from high-proliferative potential colony-forming cells (HPP-CFC). HPP-CFC were defined as progenitors giving rise to colonies of approximately 1 ϫ 10 4 to 1 ϫ 10 6 cells.
Delta (⌬) culture and secondary CFC assays
The proliferative potential of FL progenitors were also assessed in liquid cultures (⌬ cultures). Details on the use of the ⌬-assay for measuring the expansion of progenitors during 7 days of liquid culture have been previously described. 11, 13, 15 Briefly, FL progenitors were seeded into 1 ml ⌬ cultures in the presence of serum-deprived culture medium and KL ϩ GM-CSF, used at 20 ng/ml each. After 1 week of growth in 24-well tissue culture plates (Falcon; Becton Dickinson) the culture cellularity and the number of CFC responsive to KL ϩ GM-CSF were determined. The number of primary HPP-CFC and LPP-CFC were determined in parallel clonal cultures stimulated with KL ϩ GM-CSF. The number of cells and CFC (secondary HPP-CFC and LPP-CFC) recovered from ⌬ cultures are presented as a fold increase (⌬-value) over input numbers. In this study, the liquid cultures were initiated with 5 ϫ 10 4 to 2 ϫ 10 5 TFL cells and with 1200 to 5000 CD34 ϩ/ϩϩ selected FL cells, in 1 ml of serum-deprived medium supplemented with growth factors as described. Secondary CFC were assayed from 1250 to 1800 ⌬-cultured cells diluted 20-to 500-fold depending on the degree of cellular expansion.
Microbiology cultures
To assess the influence of ex vivo processing on the contamination of fetal liver by bacterial, fungal or Chlamydia organisms, cultures were performed before and after CD34 ϩ/ϩϩ cell selection using the US Pharmacopoeia Assay at the UCSF Microbiology and Virology Laboratories. 600 l of the starting solution of TFL cells was used for microbiology testing and shared in three tubes of supplemented trypticase soy broth (TSB), enriched thioglycollate medium and Chlamydia transport medium. 600 l of the final CD34 ϩ/ϩϩ purified suspension was taken for the same microbiological testing as above. Plates were incubated at 37°C and samples were observed for 14 days for growth of micro-organisms. Chlamydia cultures were checked on the 6th day.
Data presentation and statistical analysis
Unless specified, the data from multiple experiments were pooled and are presented as the mean Ϯ standard error (s.e.). Statistical significance of the data obtained from multiple experiments was calculated using a non-parametric unpaired Mann-Whitney test. Differences in the data were considered significant when P р 0.05.
Results
Comparison of different methods for the enrichment of human FL progenitors
A total of 288 FLs between 16 and 24 weeks of amenorrhea were analyzed for the number of cells and progenitors which can be obtained by various processing methods. The numbers of TFL, LDFL and GPA Ϫ LDFL cells recovered are shown in Figure 1 . The median number of TFL cells was 1.9 ϫ 10 9 (range 3.9 ϫ 10 8 to 1.1 ϫ 10
10
, n = 81). Figure 1a shows variations in TFL cell counts according to gestational age. These results do not necessarily reflect biological phenomena but, rather reveal the practical yield of TFL cells that can be expected from frequently fragmented FLs obtained after abortion. Wide cellularity ranges can be explained by the variation in the size of the FLs at harvesting time. That variation allows some 16-to 19-week FLs to exceed the cellularity of 20-week or older livers. Despite these variations, statistically significant differences in the number of cells that could be obtained from livers over 20 weeks of gestation were observed for some of the possible comparisons made with livers under 19 weeks of amenorrhea.
Density-step centrifugation was analyzed as a potential starting point for further purification of fetal HSCs, 10 as it has been used for adult BM and umbilical cord blood (UCB). The median number of LDFL cells (Figure 1b ) recovered was 2.3 ϫ 10 8 (range 7.3 ϫ 10 6 to 1.8 ϫ 10 9 , n = 211), representing a median 12% of starting TFL cells. Density separation was intended to remove most erythrocytes but failed to do so because of the large number of immature, nucleated red cells present in the FL. 16 Indeed, a median 82% of LDFL cells were removed by further depletion of GPA ϩ cells. The median number of GPA Ϫ LDFL cells (Figure 1c ) was 4.2 ϫ 10 7 (range = 4.7 ϫ 10 6 to 6.5 ϫ 10 8 , n = 174), representing a median 2% of TFL cells. Interestingly, no statistically significant difference in the number of GPA Ϫ LDFL cells was seen between any of the gestational ages. We have also noted that the fetal hepatocytes are readily killed by repeated centrifugation and that the resulting cellular debris leads to extensive clumping of cells. Consequently, the isolation of LDFL cells resulted in very wide ranges in recoveries, even when large numbers of experiments were performed by the same experimental operator. The unpredictability of the densitystep centrifugation procedure leads us to not recommend it as a first step in the processing of FL tissues.
We also tested the efficiency of sedimentation with 3% gelatin or 5% albumin, and density centrifugation with 25% albumin to enrich CD34 ϩ/ϩϩ cells. 12 Analysis of CD34 ϩ/ϩϩ recovery in the supernatant of each of the three methods showed that 25% albumin gave a mean 68% recovery (n = 3), while with 5% albumin and 3% gelatin recovery was 37% (n = 2) and 36% (n = 5), respectively. Using 3% gelatin was considered a complex time-consuming procedure (about 50 min). The higher recovery of CD34
ϩ/ϩϩ cells with 25% albumin directly reflected its weak capacity to remove clumps, because of its high density. Thus, none of these methods was found to be reliable, effective or practical for clinical use. Filtration through 105 m and 70 m sieves was found to be fast and effective in producing a suspension of single cells and removing clumps of dead cells, although accomplishing little in the way of enriching progenitors and HSCs (data not shown). Therefore, simple filtration of the TFL suspension through a mesh, before and after antibody labeling, was used to remove clumps of cells found to interfere with the isolation of CD34 ϩ/ϩϩ cells in the subsequent steps of the isolation procedure.
Phenotypic analyses suggests a high number of HSCs in the FL
The total CD34
ϩ/ϩϩ population represented a mean 2.9% (range 1% to 7.1%, n = 18) of TFL cells. Figure 2 displays the evolution of CD34 ϩ/ϩϩ number according to gestational age. The peak cellularity was observed at 20 weeks, but no significant differences were apparent according to ges- Figure 3 , to estimate the content of these overlapping cell populations in FLs (Table 1) . 20 The most conservative estimate of HSC content in the FL was made based on the CD34 ϩϩ CD38 Ϫ phenotype, the mean number of these cells was 2. 
T and NK cells are present in FLs of 16 to 24 weeks of gestation
Phenotypic analyses showed that a mean of 1.7 ϫ 10 7 TFL cells expressed CD3 (Table 1) . A statistically significant difference was observed toward a higher CD3 ϩ number at 17 weeks when compared to 20 weeks of amenorrhea. NK cell numbers were assessed using a CD56 ϩ CD3 Ϫ staining and were found to represent a mean of 4.7 ϫ 10 7 /FL, without any statistically significant differences according to gestational age.
FL contains high numbers of early progenitors with an extensive proliferative potential
CFC numbers were determined as another predictor of the engraftment potential of FL cells (Table 2) . A mean number of 1.01 ϫ 10 7 CFC were detected per FL at an average frequency of 235 CFC/1 ϫ 10 5 TFL cells. Since the vast majority of total CFC are not HSC, the colonies were subdivided based on size to better provide an estimate of the number of early progenitors. FL has been shown to contain multipotent HPP-CFC, progenitors capable of giving rise to large myeloid colonies containing 1 ϫ 10 4 to 1 ϫ 10 6 cells per colony. 11 Although it is unlikely that all HPP-CFC are HSC, measuring HPP-CFC does provide an estimate of the numbers of primitive progenitors. A mean of 12 HPP-CFC/1 ϫ 10 5 TFL cells was detected, representing a total number of 4.1 ϫ 10 5 HPP-CFC/FL. The more mature population of LPP-CFC accounted for the remainder of the total CFC.
Progenitors were measured using serum-deprived cultures, with KL and GM-CSF as growth factors. These serum-deprived culture conditions were used to eliminate the variability introduced by FBS lots. The serum-deprived medium also supported the growth of a greater number of colonies in the presence of KLϩGM-CSF than cultures containing FBS (Figure 4 ). There was no growth in the absence of added cytokines in serum-deprived medium in contrast to the variable numbers of colonies which grew in response to different batches of FBS.
To further measure the functional status of the earliest hematopoietic progenitors the expansion potential of TFL cells was determined by culturing these cells for 1 week in liquid cultures after which secondary CFC numbers were determined. This assay, the ⌬ assay, has been previously shown to be able to measure the most primitive fraction of progenitors among the compartment of HPP-CFC. The ⌬ assay discriminates between those HPP-CFC capable of generating secondary HPP-CFC from those which are more mature and generate only LPP-CFC. HPP-CFC capable of generating secondary HPP-CFC have been shown to have the phenotype of candidate HSC, ie CD34 ϩϩ CD38 Ϫ . 11 Cultured TFL cells generated a mean 10-fold expansion (n = 5) in secondary CFC. However, HPP-CFC expanded only three-fold (n = 3). A mean 9.8 ϫ 10 7 secondary CFC were HPP-CFC, n = 9). These data exemplify the capacity of FL cells to undergo extensive ex vivo proliferation. Measuring this proliferative potential also provides a simple means of measuring the recovery of viable early progenitors/HSC after positive selection of CD34 ϩ cells.
Purification of FL CD34 ϩ/ϩϩ cells results in large numbers of early progenitors, essentially free of T cells
Positive selection of FL CD34
ϩ/ϩϩ cells was achieved using the Baxter Isolex 50 device. This device is not approved for human use, but the reagents are identical to those used in the larger scale device designed for clinical use. For the first two experiments, 9.4 ϫ 10 5 and 1.1 ϫ 10 7 CD34
ϩ/ϩϩ cells were recovered after processing ( Table 3) . As CD34 ϩ/ϩϩ cell recovery was low, corrections were brought to the purification procedure that allowed us to achieve better results. The chief problem of low target cell recovery appeared to result from binding of the magnetic beads by dead FL cells, which blocked binding of the target cells and resulted in some non-specific binding of CD34 Ϫ FL cells. This problem was noticeably reduced by filtration of the TFL suspension before and after labeling with the CD34 MoAb.
Employing filtration of the TFL cells, a purity of 74% and recovery of 29% of CD34 ϩ/ϩϩ cells was achieved (Table 3) . Interestingly, phenotypic analyses showed that recoveries of candidate HSCs, CD34 ϩϩ CD38 Ϫ (30% recovery) and CD34 ϩϩ CD4 ϩ cells (52% recovery), were higher than for CD34 ϩ/ϩϩ cells in general ( Figure 5 ). CFC assays further confirmed these data, indicating that recovery of primary HPP-CFC was 38% compared to the recovery of only 15% of LPP-CFC. Moreover, 41% of secondary Comparison of colony formation by light density FL cells cultured under either serum-replete or serum-deprived conditions. Four different lots of FBS were tested. FBS lot 1 was obtained from StemCell Technologies and was recommended for the growth of human myelopoietic long-term cultures. FBS lots 2-4 were selected at random from Gemini-BioProducts. No background colony formation was detected in serum-deprived cultures in the absence of any added growth factors (arrow), whereas in response to 20 ng/ml KL ϩ 20 ng/ml GM-CSF the greatest number of colonies were generated in serum-deprived cultures. a ND, none detected. Number in parenthesis was determined based on the assumption that a single CD3 ϩ cell had been detected by the flow cytometric analysis. b FL cells were filtered before and after labeling with MoAb against CD34.
HPP-CFC were recovered compared to 20% of secondary LPP-CFC. The numbers of secondary CFC generated from the selected FL cells increased 13-fold over the numbers of primary CFC, and secondary HPP-CFC expanded threefold over primary HPP-CFC. These results are comparable to the progenitor expansions observed when TFL cells were cultured. Thus, the phenotypic and functional data demonstrate a preferential enrichment of early progenitors/HSCs over the total population of CD34 ϩ/ϩϩ cells. Processing of FLs using the Isolex system was also found to be very effective at depleting T cells (Table 3) . Phenotypic analysis of CD3 ϩ cells showed a mean 99.96% depletion of T cells, with only a mean 6.5 ϫ 10 3 CD3 ϩ cells remaining after processing.
Purification of FL progenitors and HSCs results in progenitors free of microbial contamination
We tested FLs before and after the selection procedure for microbial contamination. In one case, a Lactobacillus species was isolated from TFL before purification. At the end of the selection procedure, no bacterial, fungal or Chlamydia organisms could be isolated from the selected FL cells (n = 3).
Discussion
Despite the demonstrated proliferative advantage of FL HSCs over adult HSCs, 2,3 only two durable in utero transplants have been reported out of the 12 transplants reported using first trimester FL cells. This low success rate is likely due, in part, to difficulties in achieving in utero engraftment in some patients. 4, 7, 8 Nonetheless, the development of FL cells as a source of transplantable HSCs depends on the ability to harvest a sufficient quantity of FL cells safe for transplantation. Therefore, we studied FLs older than 16 weeks of gestation as a potential source of HSCs instead of following the approach of past studies which focused on younger, first trimester FLs. In this study we have demonstrated that second trimester FL is a rich source of candidate HSCs comparable with other sources of HSCs currently used for transplantation. We developed a clinically applicable protocol to process these cells by positive selection of CD34 ϩ/ϩϩ cells which yielded progenitors essentially free of mature T cells and free of microbial contamination.
The total number of CD34 ϩ/ϩϩ cells available from a graft has been used to estimate the engraftment potential of different HSC sources. For BM allografts a threshold of 1 ϫ 10 6 CD34 ϩ/ϩϩ cells/kg recipient body weight is usually recommended, 23 while in peripheral blood allografts, the threshold CD34 ϩ/ϩϩ cell dose has been reported to be 2.5 ϫ 10 6 /kg. 24 We found in the present study that the 1.3 ϫ 10 8 CD34 ϩ/ϩϩ cells present in an average FL between 16 and 24 weeks of gestation compares well with a typical BM graft that contains 1 to 4 ϫ 10 8 CD34
ϩ/ϩϩ cells 3 and surpasses a typical UCB donation containing 3 to 8 ϫ 10 6 CD34 ϩ/ϩϩ cells. 12, 25 The number of available CD34 ϩ/ϩϩ FL cells may, therefore, allow for the transplantation of a recipient weighing 50 to 100 kg. Although some studies showed a correlation between engraftment and the number of CD34 ϩ/ϩϩ cells, other factors with a potential modifying influence on engraftment must also be considered. These factors include the cellular composition of the donor HSC sources, the developmental age of the HSCs, the degree of histocompatibility between donor and recipient, the health status of the recipients, and the regime used to prepare the recipients for transplantation. 26 FLs harvested from first trimester abortions have, thus far, received the greatest attention as a source of transplantable HSC because of the low numbers of T cells found in these tissues. However, when compared to first trimester FLs, CD34 ϩ/ϩϩ numbers from FLs of 16 to 24 weeks of gestation were 300-fold higher than in 6-to 8-week FLs and over 100-fold higher than 13-to 15-week FLs. 27 An interesting observation made during the course of these studies is that although the number of TFL cells increased between the 16th and 24th week of fetal development, no significant differences were apparent in the number of FL CD34 ϩ/ϩϩ cells. These data suggest that as the age of the liver increases beyond 16 weeks the content in hematopoietic progenitors may plateau. This plateau in liver hematopoiesis occurs at the time when hematopoiesis in the BM is rapidly increasing. 28, 29 Although the FLs with which we worked were not intact, making a definitive conclusion on the plateau of progenitor content in the FL impossible, our observation on progenitor content is of practical benefit. Since the younger FLs have fewer cells but the same progenitor content, processing of these younger livers may pose fewer problems associated with the CD34 Ϫ liver cells. A more accurate estimate of the engraftment potential of different hematopoietic tissues may come from measurements of the content of candidate HSCs in a graft. Cells expressing the CD34 antigen represent a heterogeneous cell population of which most are already committed progeni- Colony assays were also performed to further estimate the engraftment potential of FL cells. An average of 1.0 ϫ 10 7 CFC/FL were detected. The numbers of CFC were measured using defined culture conditions that can easily be duplicated by other investigators to allow better comparisons of CFC numbers between laboratories. Both HPP-CFC, a primitive multipotent progenitor, and LPP-CFC were detected using the CFC assay conditions described. Since the developmental age of hematopoietic progenitors is a factor in their potential to form colonies in vitro, a comparison between the numbers of FL CFC and UCB CFC is likely to be the most relevant in estimating the potential of FL cells to engraft. The number of myeloid and mixed-lineage CFC detected from a single UCB harvest has been reported to range from 5 ϫ 10 5 to 7 ϫ 10 5 . 33, 34 Thus, the number of CFC available from a single FL is over 10-fold greater than from UCB.
The ability of selected CD34 ϩ/ϩϩ cells to engraft in humans has been demonstrated. 35, 36 Positive selection of CD34 ϩ/ϩϩ cells, although already reported with adult BM, peripheral blood, and UCB, 12, 25, 35, 37, 38 has never been reported with FL. In this study, we showed that selection of FL CD34 ϩ/ϩϩ cells can be achieved with minor adaptations of the manufacturer's recommendations. Several approaches to enriching FL progenitors before positive selection were investigated, but were not found to be reliable. Critical to the success of the selection procedure was the introduction of two filtration steps used to remove cell clumps and debris before and after antibody labelling. These modifications increased the purity and yield of CD34 ϩ/ϩϩ cells. It should be noted that the yield of CD34 ϩ/ϩϩ cells after processing was only 29% at best and that further improvements in the processing of the FLs need to be made before the full hematopoietic potential of the FL can be utilized for transplantation. Furthermore, we observed a preferential enrichment of CD34 ϩϩ CD38 Ϫ and CD34 ϩϩ CD4 ϩ candidate HSCs over the total population of CD34 ϩ/ϩϩ cells, and a preferential selection of HPP-CFC over LPP-CFC. These results are promising insofar as the early progenitors are considered to be the cells responsible for long-term engraftment, as opposed to the more mature progenitors responsible for early and transient engraftment. 39 In other respects, purification of CD34 ϩ/ϩϩ cells also resulted in a deep depletion of T cells. This result is equally important as T cell depletion is presently considered as the first factor for GVHD prophylaxis. 40, 41 Microbial contamination of FLs has been a major problem limiting the use of these tissues for transplantation requiring any processing procedure to be effective in eliminating microbial contamination as well as enrich for HSCs. After vaginal abortion, rates of contamination as high as 86% have been reported for FL cells. 42 This rate of contamination decreased to 9% with the use of antibiotics in the transport medium. 43 Reported rates of bacterial contamination in BM and peripheral blood collections have ranged from 0 to 17%. [44] [45] [46] [47] [48] [49] [50] We showed in our study that the purification of FL CD34 ϩ/ϩϩ cells in the presence of antimicrobial agents could provide grafts free of contamination. The lack of contamination can be explained by the large reduction in tissue size, effects of repeated washes during the selection procedure, and the effect of the antibiotic solution used through most of the processing procedure. The fetal tissues must also be tested for the possibility of viral contamination by serum analyses of the maternal donor and analyses of the FLs for specific viral pathogens. We have previously reported on our protocol for harvesting fetal tissues, which was established to balance the ethical concerns regarding fetal tissue use with the requirements for quality control of the fetal specimens. 9 Our experience has demonstrated that the majority of processed FLs are free of microbial and specific viral contamination.
FLs ranging from 16 to 24 weeks of gestation appear to be an excellent source of HSC for in utero transplantation and possibly post-natal transplantation as well. Although there is substantial evidence in animals that FL cells can repopulate the hematopoietic system of an adult, [51] [52] [53] [54] [55] [56] [57] [58] there is no conclusive evidence that human FL cells can engraft in the environment of the adult human BM. Differences in growth properties and the expression of adhesion molecules between fetal and adult progenitors have been observed that question the suitability of FL cells for adult transplantation. 59, 60 Further research into the differences between fetal and adult HSC is required before the use of fetal HSC for adult transplantation is considered. We are currently also evaluating the potential of fetal BM cells, harvested from fetuses of the same gestational ages, as an additional source of HSC. Combining FL and fetal BM cells from the same donor will further increase the number of progenitors and HSC available for transplantation. The ex vivo growth properties of fetal tissues also make these tissues excellent candidates for progenitor expansion protocols which can be further used to increase the number of progenitors available for transplantation. 61 The proliferative nature of fetal HSC also makes these cells excellent targets for genetic modification using gene therapy vectors that require the proliferation of host cells. 31 Successful transduction of fetal HSC would open the possibility of genetically modifying fetal HSC to give them a proliferative advantage over endogenous HSC in the in utero transplant setting or, possibly, for the delivery of desirable gene products in the post-natal transplant setting.
